Therapeutic Area | MeSH |
---|---|
nervous system diseases | D009422 |
mental disorders | D001523 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ADDERALL XR 25 | Takeda | N-021303 RX | 2002-05-22 | 1 products, RLD |
ADDERALL XR 5 | Takeda | N-021303 RX | 2002-05-22 | 1 products, RLD |
ADDERALL XR 15 | Takeda | N-021303 RX | 2002-05-22 | 1 products, RLD |
ADDERALL XR 10 | Takeda | N-021303 RX | 2001-10-11 | 1 products, RLD |
ADDERALL XR 20 | Takeda | N-021303 RX | 2001-10-11 | 1 products, RLD |
ADDERALL XR 30 | Takeda | N-021303 RX | 2001-10-11 | 1 products, RLD, RS |
MYDAYIS | Takeda | N-022063 RX | 2017-06-20 | 4 products, RLD, RS |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
attention deficit disorder with hyperactivity | EFO_0003888 | D001289 | F90 |
narcolepsy | EFO_0000614 | D009290 | G47.4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 5 | 5 | 2 | — | 10 |
Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | 1 | 1 | 1 | — | 2 |
Motivation | D009042 | — | — | — | — | — | 1 | — | 1 |
Deception | D008192 | — | — | — | — | — | 1 | — | 1 |
Substance-related disorders | D019966 | EFO_0003890 | F13 | — | — | — | 1 | — | 1 |
Conduct disorder | D019955 | EFO_0004216 | F91 | — | — | — | 1 | — | 1 |
Covid-19 | D000086382 | — | U07.1 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cocaine-related disorders | D019970 | — | F14 | — | 3 | 2 | — | — | 3 |
Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 2 | 2 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Short-term memory | D008570 | EFO_0004335 | — | — | 1 | — | — | — | 1 |
Affect | D000339 | — | — | — | 1 | — | — | — | 1 |
Narcolepsy | D009290 | HP_0030050 | G47.4 | — | 1 | — | — | — | 1 |
Idiopathic hypersomnia | D020177 | — | G47.11 | — | 1 | — | — | — | 1 |
Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 1 | — | — | — | 1 |
Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
Depression | D003863 | — | F33.9 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | — | — | — | — | 1 |
Hemodynamics | D006439 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Amphetamine aspartate |
INN | — |
Description | 1-phenylpropan-2-amine is a primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group. |
Classification | Small molecule |
Drug class | CNS stimulant, anorectic |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(N)Cc1ccccc1.NC(CC(=O)O)C(=O)O |
PDB | — |
CAS-ID | 156-34-3 |
RxCUI | — |
ChEMBL ID | CHEMBL1200377 |
ChEBI ID | — |
PubChem CID | 3007 |
DrugBank | DB00182 |
UNII ID | — |